在日本的老年人中,他类药物的使用和帕金森病的风险:使用长寿改善和公平证据研究的嵌套病例控制研究
Sanyu Ge1, Ling Zha1, Yasuyoshi Kimura2
1Division of Environmental Medicine and Population Sciences, Department of Social Medicine, Graduate School of Medicine, Osaka University, Suita, 565-0871, Osaka, Japan.
Brain communications
|June 19, 2024
概括
日本老年人使用静止剂与帕金森病风险降低有关. 较高的累积他类药物剂量显示出保护作用,而较低的剂量与风险增加有关.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类药物使用与帕金森病 (PD) 风险之间的关系尚不清楚,特别是在老年人群中.
- 日本的超级老龄化社会需要对影响神经退行性疾病 (如PD) 的因素进行研究.
研究的目的:
- 调查65岁及以上的日本人使用他类药物与患帕金森病的风险之间的关联.
主要方法:
- 使用2014年4月至2020年12月的医疗和长期护理索赔数据,采用了一个嵌套病例控制研究设计.
- 参与者 (N=56,186) 包括9,397例帕金森病病例和46,789例对照,根据年龄,性别,市政和队列进入年份进行匹配.
- 条件逻辑回归分析估计了他类药物使用和PD风险的概率比率 (ORs) 和95%置信区间 (CI),包括剂量反应分析.
主要成果:
- 斯坦丁使用与帕金森病风险降低有显著的关联 (OR:0.61;95% CI:0.56-0.66).
- 剂量反应分析表明,较高的累积他类药物剂量 (>180总标准每日剂量) 显示出最强的保护作用 (OR:0.30;95% CI:0.25-0.35).
- 相反,较低的累积剂量 (1-30个标准每日总剂量) 与风险增加有关 (OR: 1.30; 95% CI: 1.12-1.52).
结论:
- 在日本老年人中,使用他类药物与帕金森病风险降低有关.
- 较高的累积他类药物暴露表明具有保护作用,而较低的暴露可能与风险增加有关.
- 需要进一步的研究来阐明这种剂量依赖的关联背后的机制.
相关概念视频
Parkinson's Disease: Treatment
255
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
255
Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
646
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
646
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


